179 related articles for article (PubMed ID: 32259323)
21. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
[TBL] [Abstract][Full Text] [Related]
22. Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
Carden MA; Smith S; Meany H; Yin H; Alazraki A; Rapkin LB
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28052556
[TBL] [Abstract][Full Text] [Related]
23. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
[TBL] [Abstract][Full Text] [Related]
24. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
[TBL] [Abstract][Full Text] [Related]
25. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
26. Renal medullary carcinoma involving serous cavity fluids: a cytomorphologic study of 12 cases.
Miller DL; Ribeiro EA; Roy-Chowdhuri S; Illei PB; Siddiqui MT; Ali SZ
J Am Soc Cytopathol; 2021; 10(2):187-196. PubMed ID: 32651128
[TBL] [Abstract][Full Text] [Related]
27. Renal medullary carcinoma in a white adolescent with sickle cell trait.
Daher P; Bourgi A; Riachy E; Khoury A; Rehayem C; Sader-Ghorra C
J Pediatr Hematol Oncol; 2014 Jul; 36(5):e285-9. PubMed ID: 24517963
[TBL] [Abstract][Full Text] [Related]
28. Renal Medullary Carcinoma: a Report of the Current Literature.
Blas L; Roberti J; Petroni J; Reniero L; Cicora F
Curr Urol Rep; 2019 Jan; 20(1):4. PubMed ID: 30656488
[TBL] [Abstract][Full Text] [Related]
29. Renal medullary carcinoma and ABL gene amplification.
Simpson L; He X; Pins M; Huang X; Campbell SC; Yang XJ; Perlman EJ; Bergan RC
J Urol; 2005 Jun; 173(6):1883-8. PubMed ID: 15879768
[TBL] [Abstract][Full Text] [Related]
30. Targeting epigenetics in sarcomas through EZH2 inhibition.
Italiano A
J Hematol Oncol; 2020 Apr; 13(1):33. PubMed ID: 32264965
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.
Lipkin JS; Rizvi SM; Gatalica Z; Sarwani NE; Holder SL; Kaag M; Drabick JJ; Joshi M
Cancer Biol Ther; 2015; 16(1):28-33. PubMed ID: 25692619
[TBL] [Abstract][Full Text] [Related]
32. Immunologic Correlates of the Abscopal Effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 Inhibition and Radiotherapy.
Gounder MM; Zhu G; Roshal L; Lis E; Daigle SR; Blakemore SJ; Michaud NR; Hameed M; Hollmann TJ
Clin Cancer Res; 2019 Apr; 25(7):2064-2071. PubMed ID: 30642912
[TBL] [Abstract][Full Text] [Related]
33. Renal Medullary Carcinoma and Sickle Cell Trait: A Push for Early Diagnosis and Intervention Report of Two Cases.
Carter SA; Walker AN
J Natl Med Assoc; 2017 Spring; 109(1):63-65. PubMed ID: 28259220
[TBL] [Abstract][Full Text] [Related]
34. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
Shapiro DD; Zacharias NM; Tripathi DN; Karki M; Bertocchio JP; Soeung M; He R; Westerman ME; Gao J; Rao P; Lam TNA; Jonasch E; Perelli L; Cheng EH; Carugo A; Heffernan TP; Walker CL; Genovese G; Tannir NM; Karam JA; Msaouel P
Clin Transl Med; 2023 May; 13(5):e1267. PubMed ID: 37226898
[TBL] [Abstract][Full Text] [Related]
35. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
[TBL] [Abstract][Full Text] [Related]
36. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
Adelaiye-Ogala R; Budka J; Damayanti NP; Arrington J; Ferris M; Hsu CC; Chintala S; Orillion A; Miles KM; Shen L; Elbanna M; Ciamporcero E; Arisa S; Pettazzoni P; Draetta GF; Seshadri M; Hancock B; Radovich M; Kota J; Buck M; Keilhack H; McCarthy BP; Persohn SA; Territo PR; Zang Y; Irudayaraj J; Tao WA; Hollenhorst P; Pili R
Cancer Res; 2017 Dec; 77(23):6651-6666. PubMed ID: 28978636
[TBL] [Abstract][Full Text] [Related]
37. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
[TBL] [Abstract][Full Text] [Related]
38. Renal Medullary Carcinoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
Haupt T; Akinyemi O; Raju RA; Wadley AE; Nnorom S; Aponte V; Thelus J; Tonkin JB; Coleman PW; Metwalli AR
J Surg Res; 2023 Dec; 292():1-6. PubMed ID: 37567029
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.
Ramakrishnan S; Granger V; Rak M; Hu Q; Attwood K; Aquila L; Krishnan N; Osiecki R; Azabdaftari G; Guru K; Chatta G; Gueron G; McNally L; Ohm J; Wang J; Woloszynska A
Cell Death Differ; 2019 Oct; 26(10):2100-2114. PubMed ID: 30692641
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
